Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical ...
Business Insider6h
Positive Outlook for Oruka Therapeutics: Promising Developments with ORKA-001
Tyler Van Buren has given his Buy rating due to a combination of factors surrounding Oruka Therapeutics’ promising developments with their lead antibody, ORKA-001. The extended half-life of ORKA-001, ...
TD Cowen downgrades Kronos Bio (KRON) to a Hold
Kronos Bio (KRON – Research Report) received a Hold rating and price target from TD Cowen analyst Tyler Van Buren yesterday. The ...
The New York Times17h
New York Times - Top Stories
At Mar-a-Lago, ‘Uncle’ Elon Musk Puts His Imprint on the Trump Transition He’s on the patio. He’s on the golf course. Everywhere President-elect Trump looks, there is the world’s richest ...